Phase 3 clinical trial results released this month show Besremi is effective for ET patients

[Eferret]

SURPASS-ET trial compared effectiveness of anagrelide with Besremi for ET patients.

Besremi was more effective in reducing allele burden and controlling blood counts.

Hopefully Besremi will be approved soon as a first-line treatment for ET.

targetedonc.com/view/ropegi...

[EPguy]

ET pts have a great need for options beyond HU and Ana. This is a big step there. The biggest surprise to me is how ineffective Ana was, only 6% clinical responders (I assume this is mostly PLT counts). As with most Rux studies the pts here were hydroxyurea resistant or intolerant, so the good result with IFN is a big advance.

This is the study:

clinicaltrials.gov/study/NC...

Primary completion was last Nov so the study is finished. It is "second-line therapy " so with the HU-first requirement this approval may be like Rux, required to try HU first.

They measured CALR and MPL mutations along with Jak2, so it may be the first large study to specifically measure allele reduction via IFN for the other two ET mutations.

[hunter5582]

Very hopeful finding. It would be best for ET patients if Besremi ends up as a first-line treatment option with no requirement to first fail on HU.

[Grapefruitlohoff]

that’s an amazing news! One point I do find unusual is that the study seems to focus on patients with very high WBC counts, which is not very common if I’m not mistaken. Hope that won’t restrict the applicability of the trial results too much.

[Spanelmad]

Fingers crossed it gets approved as a first line treatment.As I'm hu /inf intolerant, I've been told angaralide would be my next drug and that's not effective in reducing the risk of progression